Abstract
The platinum compounds cisplatin and carboplatin are active against a wide range of adult and pediatric malignancies. Whereas both exert their cytotoxic effect by incorporating into DNA, they have substantially different systemic and cellular pharmacology. In addition, their toxicity profiles are much different. Substantial interpatient pharmacokinetic variability and narrow therapeutic indexes of the two agents led to the development of several dosing strategies. Although these strategies reduce pharmacokinetic variability, their effect on improving patient outcome remains to be determined.
Reference47 articles.
1. Cisplatin
2. What is the place of carboplatin in paediatric oncology?
3. Plasma levels of urinary excretion of filterable platinum species following bolus injection and iv infusion of cis‐dichlorodiammineplatinum(II) in man;Patton TF;Cancer Treat Rep,1978
4. Pharmacokinetics of free and total platinum species after short‐term infusion of cisplatin;Vermorken JB;Cancer Treat Rep,1984
5. Cisplatin-associated neurotoxicity
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献